Sorafenib in Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation

Lekili M., MÜEZZİNOĞLU T., Nese N., TEMELTAŞ G.

Journal of the Chinese Medical Association, cilt.73, sa.5, ss.262-264, 2010 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 73 Sayı: 5
  • Basım Tarihi: 2010
  • Doi Numarası: 10.1016/s1726-4901(10)70056-3
  • Dergi Adı: Journal of the Chinese Medical Association
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.262-264
  • Anahtar Kelimeler: metastasis, renal cell cancer, sarcomatoid differentiation, sorafenib
  • Manisa Celal Bayar Üniversitesi Adresli: Evet

Özet

Targeted therapy in the management of metastatic renal cell cancer has been recently introduced to urology practice. The drugs used for management are used in a very limited number of patients and only for clear cell histology. We present a case where we administered sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, to a patient with metastatic renal cell carcinoma of clear cell histology. We found that our results were different from those of previously reported studies, because sarcomatoid differentiation was evident in a histological examination of this case. There was an excellent response to sorafenib. This case report might provide evidence that antiangiogenic agents may be active in any histological type of renal cell carcinoma. However, there are no available data to demonstrate the duration of response and survival benefit. © 2010 Elsevier.